References:

1.HicksDG.Immunohistochemistryinthediagnosticevaluationofbreastlesions.ApplImmunohistochemMolMorph.2011;19:501-5.
2.MoriyaT,etal.Newtrendsofimmunohistochemistryformakingdifferentialdiagnosisofbreastlesions.MedMolMorphol.2006;39:8-13.
3.YehIT,MiesC.Applicationofimmunohistochemistrytobreastlesions.ArchPatholLabMed.2008;132:349-57.
4.LerwillMF.Currentpracticalapplicationsofdiagnosticimmunohistochemistryinbreastpathology.AmJSurgPathol.2004;28:1076-91.
5.MoriyaT,etal.Usefulnessofimmunohistochemistryfordifferentialdiagnosisbetweenbenignandmalignantbreastlesions.BreastCancer.2009;16:173-8.
6.OtterbachF,etal.Cytokeratin5/6immunohistochemistryassistsindifferentialdiagnosisofatypicalproliferationsofthebreast.Histopathology.2000;37:232-40.
7.Lacroix-TrikiM,etal.Valueofcytokeratin5/6immunostainingusingD5/16B4antibodyinthespectrumofproliferativeintraepitheliallesionsofthebreast.Acomparativestudywith34betaE12antibody.VirchowsArch.2003;442:548-54.
8.BoeckerW,etal.Usualductalhyperplasiaofthebreastisacommittedstem(Progenitor)celllesiondistinctfromatypicalductalhyperplasiaandductalcarcinomainsitu.JPathol.2002;198:458-67.
9.KooJS,etal.ComparisonofImmunohistochemicalstaininginbreastpapillaryneoplasmofcytokeratin5/6andp63incoreneedlebiopsiesandsurgicalexcisions.ApplImmunohistochemMolMorph.2012;20:108-15.
10.IchiharaS,etal.Doubleimmunostainingwithp63andhighmolecular-weightcytokeratinsdistinguishesborderlinepapillarylesionsofthebreast.PathInt.2007;57:126-32.
11.LivasyCA,etal.Phenotypicevaluationofthebasal-likesubtypeofinvasivebreastcarcinoma.ModPathol.2006;19:264-71.
12.LaaksoM,etal.Cytokeratin5/14-positivebreastcancer:truebasalphenotypeconfinedtoBRCA1tumors.ModPathol.2005;18:1321-8.
13.BhargavaR,etal.CK5ismoresensitivethanCK5/6inidentifyingthe“basal-like”phenotypeofbreastcarcinoma.AmJClinPathol.2008;130:724-30.
14.JainRK,etal.Atypicalductalhyperplasia:interobserverandintraobservervariABIlity.ModPathol.2011;24:917-23.
15.CenterforDiseaseControlManual.Guide:SafetyManagement,NO.CDC-22,Atlanta,GA.April30,1976“DecontaminationofLaboratorySinkDrainstoRemoveAzideSalts.”
16.ClinicalandLaboratoryStandardsInstitute(CLSI).ProtectionofLaboratoryWorkersfromOccupationallyAcquiredInfections;ApprovedGuideline-FourthEditionCLSIdocumentM29-A4Wayne,PA2014.

Biocare医学教育外展计划通过Biocare仪器和试剂的技术教育为我们目前和潜在的客户提供支持。教育外展团队致力于通过教育指导，材料和计划使每个客户成功。我们将最新的科学发现纳入我们的培训中，提供新鲜，相关的内容。我们的目标是让受训人员以信心和专业知识来培训其同事，以掌握返回实验室所需的主题知识。

Biocare医学教育推广计划提供全面的培训，在我们的教育中心和培训实验室中使科学理论与实际实践学习保持平衡。小班授课和个性化的教学模块允许在高素质的技术专家的带领下定制课程。

我们计划的范围包括

• 在加利福尼亚州康科德市的生物保健医学教育中心和培训实验室接受培训

• 网络研讨会

• 大事记

Biocare Medical是国家组织技术培训协会的骄傲，提供NSH认可的课程。